Plasma Fractionation Market

1.1. Plasma Fractionation Market Overview

1.2. Key Market Insights

1.3. Scope of the Report

1.4. Research Methodology

1.5. Frequently Asked Questions

1.6. Chapter Outlines

3.1. Chapter Overview

3.2. Introduction to Blood Plasma

3.2.1. Plasma Collection

3.2.2. Plasma Screening

3.2.3. Plasma Fractionation

3.3. Applications of Plasma Fractionation

3.4. Challenges Associated with Plasma Fractionation

3.5. Need for Third-party Service Providers

3.5.1. Overview of Third-party Service Providers

3.6. Future Perspectives

4.1. Chapter Overview

4.2. Plasma Fractionation: Overall Market Landscape

4.2.1. Analysis by Year of Establishment

4.2.2. Analysis by Company Size

4.2.3. Analysis by Location of Headquarters (Region)

4.2.4. Analysis by Location of Headquarters (Country)

4.2.5. Analysis by Year of Establishment and Location of Headquarters (Region)

4.2.6. Analysis by Company Size and Location of Headquarters (Region)

4.2.7. Analysis by Type of Company

4.2.8. Analysis by Location of Plasma Fractionation Facilities (Region)

4.2.9. Analysis by Location of Plasma Collection Facility

4.2.10. Analysis by Availability of Patented / Proprietary Technology

4.2.11. Analysis by Additional Fractionation Capabilities

4.2.12. Analysis by Scale of Operation

4.2.13. Analysis by Type of Plasma-derived Therapeutic Products Manufactured

4.2.14. Analysis by Therapeutic Areas of Plasma-derived Products

4.2.15. Analysis by End Users

4.2.16. Information on Plasma Fractionation Capacity and Accreditation / Certification

4.2.17. Information on Upcoming Plasma Fractionation Facilities

4.2.18. Information on Companies Previously Involved in Plasma Fractionation

5.1. Chapter Overview

5.2. Assumptions and Key Parameters

5.3. Methodology

5.4. Company Competitiveness Analysis: In-house Manufacturers

5.4.1. Players based in North America and Europe

5.4.2. Players based in Asia-Pacific and Rest of the World

5.5. Company Competitiveness Analysis: In-house Manufacturers and Contract Service Providers

5.5.1. Players based in North America and Europe

5.5.2. Players based in Asia-Pacific and Rest of the World

6.1. Chapter Overview

6.2. Companies Headquartered in North America

6.2.1. Baxter

6.2.1.1. Company Overview

6.2.1.2. Financial Information

6.2.1.3. Plasma Fractionation Portfolio

6.2.1.4. Recent Developments and Future Outlook

6.3. Companies Headquartered in Europe

6.3.1. Grifols

6.3.1.1. Company Overview

6.3.1.2. Financial Information

6.3.1.3. Plasma Fractionation Portfolio

6.3.1.4. Recent Developments and Future Outlook

6.3.2. Kedrion

6.3.2.1. Company Overview

6.3.2.2. Financial Information

6.3.2.3. Plasma Fractionation Portfolio

6.3.2.4. Recent Developments and Future Outlook

6.3.3. Octapharma

6.3.3.1. Company Overview

6.3.3.2. Financial Information

6.3.3.3. Plasma Fractionation Portfolio

6.3.3.4. Recent Developments and Future Outlook

6.4. Companies Headquartered in Asia-Pacific

6.4.1. CSL

6.4.1.2. Company Overview

6.4.1.3. Financial Information

6.4.1.4. Plasma Fractionation Portfolio

6.4.1.5. Recent Developments and Future Outlook

6.4.2. Takeda Pharmaceutical

6.4.2.1. Company Overview

6.4.2.2. Financial Information

6.4.2.3. Plasma Fractionation Portfolio

6.4.2.4. Recent Developments and Future Outlook

7.1. Chapter Overview

7.2. Partnership Models

7.3. Plasma Fractionation: Partnerships and Collaborations

7.3.1. Analysis by Year of Partnership

7.3.2. Analysis by Type of Partnership

7.3.3. Analysis by Year and Type of Partnership

7.3.4. Analysis by Purpose of Agreement

7.3.5. Analysis by Type of Plasma-derived Therapeutic Products Manufactured

7.3.6. Analysis by Type of Partner

7.3.7. Analysis by Year of Partnership and Type of Partner

7.3.8. Analysis by Type of Partnership and Type of Partner

7.3.9. Most Active Players: Analysis by Number of Partnerships

7.4. Analysis by Geography

7.4.1. Local and International Agreements

7.4.2. Intracontinental and Intercontinental Agreements

8.1. Chapter Overview

8.2. Expansion Models

8.3. Plasma Fractionation: Recent Expansions

8.3.1. Analysis by Year of Expansion

8.3.2. Analysis by Type of Expansion

8.3.3. Analysis by Year and Type of Expansion

8.3.4. Analysis by Type of Facility

8.3.5. Analysis by Location of Expanded Facility

8.3.6. Analysis by Year and Location of Expanded Facility

8.3.7. Analysis by Plasma-derived Therapeutic Products Manufactured

8.3.8. Most Active Players: Analysis by Number of Expansions

9.1. Chapter Overview

9.2. Key Assumptions and Methodology

9.2.1. Annual Plasma Fractionation Capacity

9.2.1.1. Analysis by Company Size

9.2.1.2. Analysis by Type of Plasma-derived Therapeutic Products Manufactured

9.2.1.3. Analysis by Scale of Operation

9.2.2. Analysis by Location of Plasma Fractionation Facility

9.2.3 .Analysis by Location of Headquarters

9.3. Concluding Remarks

10.1. Chapter Overview

10.2. Key Assumptions and Forecast Methodology

10.3. Global Plasma Fractionation Market (Historical, Base and Forecasted Scenario), 2017-2035

10.3.1. Plasma Fractionation Market: Distribution by Type of Company, 2017, 2023 and 2035

10.3.1.1. Plasma Fractionation Market for In-house Manufacturers, 2023-2035

10.3.1.2. Plasma Fractionation Market for Contract Service Providers, 2023-2035

10.3.2. Plasma Fractionation Market: Distribution by Scale of Operation, 2017, 2023 and 2035

10.3.2.1. Plasma Fractionation Market for Preclinical, 2023-2035

10.3.2.2. Plasma Fractionation Market for Clinical, 2023-2035

10.3.2.3. Plasma Fractionation Market for Commercial, 2023-2035

10.3.3. Plasma Fractionation Market: Distribution by Type of Plasma-derived Therapeutic Products Manufactured, 2017, 2023 and 2035

10.3.3.1. Plasma Fractionation Market for Albumins, 2023-2035

10.3.3.2. Plasma Fractionation Market for Coagulation Factors, 2023-2035

10.3.3.3. Plasma Fractionation Market for Immunoglobulins, 2023-2035

10.3.3.4. Plasma Fractionation Market for Protease Inhibitors, 2023-2035

10.3.3.5. Plasma Fractionation Market for Other Plasma-derived Products, 2023-2035

10.3.4. Plasma Fractionation Market: Distribution by Therapeutic Areas of Plasma-derived Products, 2017, 2023 and 2035

10.3.4.1. Plasma Fractionation Market for Hematological Disorders, 2023-2035

10.3.4.2. Plasma Fractionation Market for Hepatic Disorders, 2023-2035

10.3.4.3. Plasma Fractionation Market for Immunological Disorders, 2023-2035

10.3.4.4. Plasma Fractionation Market for Neurological Disorders, 2023-2035

10.3.4.5. Plasma Fractionation Market for Other Disorders, 2023-2035

10.3.5. Plasma Fractionation Market: Distribution by Demand across Key Geographical Regions, 2017, 2023 and 2035

10.3.5.1. Plasma Fractionation Market in North America, 2023-2035

10.3.5.2. Plasma Fractionation Market in Europe, 2023-2035

10.3.5.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035

10.3.5.4. Plasma Fractionation Market in Rest of the World, 2023-2035

10.3.6. Plasma Fractionation Market: Distribution by Supply across Key Geographical Regions, 2017, 2023 and 2035

10.3.6.1. Plasma Fractionation Market in North America, 2023-2035

10.3.6.2. Plasma Fractionation Market in Europe, 2023-2035

10.3.6.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035

10.3.6.4. Plasma Fractionation Market in Rest of the World, 2023-2035

List of Figures

Figure 2.1 Executive Summary: Current Market Landscape

Figure 2.2 Executive Summary: Partnerships and Collaborations

Figure 2.3 Executive Summary: Recent Expansions

Figure 2.4 Executive Summary: Capacity Analysis

Figure 2.5 Executive Summary: Market Sizing and Opportunity Analysis

Figure 3.1 Components of Blood

Figure 3.2 Components of Blood Plasma

Figure 3.3 Process of Plasmapheresis

Figure 3.4 Good Manufacturing Practices for Blood Screening

Figure 3.5 Steps Involved in Plasma Fractionation

Figure 3.6 Target Therapeutic Areas of Plasma-derived Therapies

Figure 3.7 Advantages of Third-party Service Providers

Figure 4.1 Plasma Fractionators: Distribution by Year of Establishment

Figure 4.2 Plasma Fractionators: Distribution by Company Size

Figure 4.3 Plasma Fractionators: Distribution by Location of Headquarters (Region)

Figure 4.4 Plasma Fractionators: Distribution by Location of Headquarters (Country)

Figure 4.5 Plasma Fractionators: Distribution by Year of Establishment and Location of Headquarters (Region)

Figure 4.6 Plasma Fractionators: Distribution by Company Size and Location of Headquarters (Region)

Figure 4.7 Plasma Fractionators: Distribution by Type of Company

Figure 4.8 Plasma Fractionators: Distribution by Location of Plasma Fractionation Facilities (Region)

Figure 4.9 Plasma Fractionators: Distribution by Location of Plasma Collection Facility

Figure 4.10 Plasma Fractionators: Distribution by Availability of Patented / Proprietary Technology

Figure 4.11 Plasma Fractionators: Distribution by Additional Fractionation Capabilities

Figure 4.12 Plasma Fractionators: Distribution by Scale of Operation

Figure 4.13 Plasma Fractionators: Distribution by Type of Plasma-derived Therapeutic Products Manufactured

Figure 4.14 Plasma Fractionators: Distribution by Therapeutic Areas of Plasma-derived Products

Figure 4.15 Plasma Fractionators: Distribution by End Users

Figure 5.1 In-house Manufacturers: Players based in North America and Europe

Figure 5.2 In-house Manufacturers: Players based in Asia-Pacific and Rest of the World

Figure 5.3 In-house Manufacturers and Contract Service Providers: Players based in North America and Europe

Figure 5.4 In-house Manufacturers and Contract Service Providers: Players based in Asia-Pacific and Rest of the World

Figure 6.1 Baxter: Annual Revenues, 2018-Q1 2023 (USD Billion)

Figure 6.2 Grifols: Annual Revenues, 2018-Q1 2023 (EUR Million)

Figure 6.3 Kedrion: Annual Revenues, 2018-2022 (EUR Million)

Figure 6.4 Octapharma: Annual Revenues, 2018-2022 (EUR Billion)

Figure 6.5 CSL: Annual Revenues, FY 2018 - H1 FY 2023 (USD Million)

Figure 6.6 Takeda Pharmaceutical: Annual Revenues, FY 2018 - FY 2022 (JPY Billion)

Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Distribution of Partnerships

Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Figure 7.4 Partnerships and Collaborations: Distribution by Purpose of Agreement

Figure 7.5 Partnerships and Collaborations: Distribution by Type of Plasma-derived Therapeutic Products Manufactured

Figure 7.6 Partnerships and Collaborations: Distribution by Type of Partner

Figure 7.7 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner

Figure 7.8 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner

Figure 7.9 Most Active Players: Distribution by Number of Partnerships

Figure 7.10 Partnerships and Collaborations: Distribution by Local and International Agreements

Figure 7.11 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements

Figure 8.1 Recent Expansions: Cumulative Year-wise Distribution of Expansions

Figure 8.2 Recent Expansions: Distribution by Type of Expansion

Figure 8.3 Recent Expansions: Distribution by Year and Type of Expansion

Figure 8.4 Recent Expansions: Distribution by Type of Facility

Figure 8.5 Recent Expansions: Distribution by Location of Expanded Facility

Figure 8.6 Recent Expansions: Distribution by Year and Location of Expanded Facility

Figure 8.7 Recent Expansions: Distribution by Plasma-derived Therapeutic Products Manufactured

Figure 8.8 Most Active Players: Distribution by Number of Expansions

Figure 9.1 Annual Plasma Fractionation Capacity: Distribution by Range of Installed Capacity

Figure 9.2 Annual Plasma Fractionation Capacity: Distribution by Company Size

Figure 9.3 Annual Plasma Fractionation Capacity: Distribution by Type of Plasma-derived Therapeutic Products Manufactured

Figure 9.4 Annual Plasma Fractionation Capacity: Distribution by Scale of Operation

Figure 9.5 Plasma Fractionation Capacity: Distribution by Location of Plasma Fractionation Facilities

Figure 9.6 Plasma Fractionation Capacity: Distribution by Location of Headquarters (in Million Liters)

Figure 10.1 Global Plasma Fractionation Market (Historical Trends and Forecasted Estimates), 2017-2035 (USD Billion)

Figure 10.2 Plasma Fractionation Market: Distribution by Type of Company, 2017, 2023 and 2035 (USD Billion)

Figure 10.3 Plasma Fractionation Market for In-house Manufacturers, 2023-2035 (USD Billion)

Figure 10.4 Plasma Fractionation Market for Contract Service Providers, 2023-2035 (USD Billion)

Figure 10.5 Plasma Fractionation Market: Distribution by Scale of Operation, 2017, 2023 and 2035 (USD Billion)

Figure 10.6 Plasma Fractionation Market for Preclinical Operations, 2023-2035 (USD Billion)

Figure 10.7 Plasma Fractionation Market for Clinical Operations, 2023-2035 (USD Billion)

Figure 10.8 Plasma Fractionation Market for Commercial Operations, 2023-2035 (USD Billion)

Figure 10.9 Plasma Fractionation Market: Distribution by Type of Plasma-derived Therapeutic Products Manufactured, 2017, 2023 and 2035 (USD Billion)

Figure 10.10 Plasma Fractionation Market for Albumins, 2023-2035 (USD Billion)

Figure 10.11 Plasma Fractionation Market for Coagulation Factors, 2023-2035 (USD Billion)

Figure 10.12 Plasma Fractionation Market for Immunoglobulins, 2023-2035 (USD Billion)

Figure 10.13 Plasma Fractionation Market for Protease Inhibitors, 2023-2035 (USD Billion)

Figure 10.14 Plasma Fractionation Market for Other Plasma-derived Products, 2023-2035 (USD Billion)

Figure 10.15 Plasma Fractionation Market: Distribution by Therapeutic Areas of Plasma-derived Products, 2017, 2023 and 2035 (USD Billion)

Figure 10.16 Plasma Fractionation Market for Hematological Disorders, 2023-2035 (USD Billion)

Figure 10.17 Plasma Fractionation Market for Hepatic Disorders, 2023-2035 (USD Billion)

Figure 10.18 Plasma Fractionation Market for Immunological Disorders, 2023-2035 (USD Billion)

Figure 10.19 Plasma Fractionation Market for Neurological Disorders, 2023-2035 (USD Billion)

Figure 10.20 Plasma Fractionation Market for Other Disorders, 2023-2035 (USD Billion)

Figure 10.21 Plasma Fractionation Market: Distribution by Demand across Key Geographical Regions, 2017, 2023 and 2035 (USD Billion)

Figure 10.22 Plasma Fractionation Market for North America, 2023-2035 (USD Billion)

Figure 10.23 Plasma Fractionation Market for Europe, 2023-2035 (USD Billion)

Figure 10.24 Plasma Fractionation Market for Asia-Pacific, 2023-2035 (USD Billion)

Figure 10.25 Plasma Fractionation Market for Rest of the World, 2023-2035 (USD Billion)

Figure 10.26 Plasma Fractionation Market: Distribution by Supply across Key Geographical Regions, 2017, 2023 and 2035 (USD Billion)

Figure 10.27 Plasma Fractionation Market for North America, 2023-2035 (USD Billion)

Figure 10.28 Plasma Fractionation Market for Europe, 2023-2035 (USD Billion)

Figure 10.29 Plasma Fractionation Market for Asia-Pacific, 2023-2035 (USD Billion)

Figure 10.30 Plasma Fractionation Market for Rest of the World, 2023-2035 (USD Billion)

Figure 11.1 Concluding Remarks: Current Market Landscape of Plasma Fractionators

Figure 11.2 Concluding Remarks: Partnerships and Collaborations

Figure 11.3 Concluding Remarks: Recent Expansions

Figure 11.4 Concluding Remarks: Capacity Analysis

Figure 11.5 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)

Figure 11.6 Concluding Remarks: Market Sizing and Opportunity Analysis (II/II)

List of Tables

Table 4.1 List of Plasma Fractionators

Table 4.2 Plasma Fractionators: Information on Plasma Fractionation Facilities

Table 4.3 Plasma Fractionators: Information on Plasma Collection Facilities

Table 4.4 Plasma Fractionators: Information on Patented / Proprietary Technology / Process Used

Table 4.5 Plasma Fractionators: Information on Additional Fractionation Capabilities

Table 4.6 Plasma Fractionators: Information on Scale of Operation

Table 4.7 Plasma Fractionators: Information on Type of Plasma-derived Therapeutic Products Manufactured

Table 4.8 Plasma Fractionators: Information on Therapeutic Areas of Plasma-derived Products

Table 4.9 Plasma Fractionators: Information on End Users

Table 4.10 Plasma Fractionators: Information on Plasma Fractionation Capacity and Accreditation / Certification

Table 4.11 Plasma Fractionators: Information on Upcoming Plasma Fractionation Facilities

Table 4.12 Plasma Fractionators: Information on Companies Previously Involved in Plasma Fractionation

Table 4.13 Plasma Fractionation: List of Additional Players

Table 6.1 Plasma Fractionation: List of Companies Profiled

Table 6.2 Baxter: Company Snapshot

Table 6.3 Baxter: Plasma Fractionation Portfolio

Table 6.4 Baxter: Recent Developments and Future Outlook

Table 6.5 Grifols: Company Snapshot

Table 6.6 Grifols: Plasma Fractionation Portfolio

Table 6.7 Grifols: Recent Developments and Future Outlook

Table 6.8 Kedrion: Company Snapshot

Table 6.9 Kedrion: Plasma Fractionation Portfolio

Table 6.10 Kedrion: Recent Developments and Future Outlook

Table 6.11 Octapharma: Company Snapshot

Table 6.12 Octapharma: Plasma Fractionation Portfolio

Table 6.13 Octapharma: Recent Developments and Future Outlook

Table 6.14 CSL: Company Snapshot

Table 6.15 CSL: Plasma Fractionation Portfolio

Table 6.16 CSL: Recent Developments and Future Outlook

Table 6.17 Takeda Pharmaceutical: Company Snapshot

Table 6.18 Takeda Pharmaceutical: Plasma Fractionation Portfolio

Table 6.19 Takeda Pharmaceutical: Recent Developments and Future Outlook

Table 7.1 Plasma Fractionation: Partnerships and Collaborations

Table 7.2 Plasma Fractionation: Information on Location of Partner (Country and Region)

Table 8.1 Plasma Fractionation: Recent Expansions

Table 8.2 Recent Expansions: Information on Type of Plasma-derived Therapeutic Products Manufactured

Table 9.1 Annual Plasma Fractionation Capacity: Average Capacity Per Facility by Company Size of Fractionators (Sample Data Set)

Table 9.2 Annual Plasma Fractionation Capacity: Distribution by Company Size

Table 13.1 Plasma Fractionators: Distribution by Year of Establishment

Table 13.2 Plasma Fractionators: Distribution by Company Size

Table 13.3 Plasma Fractionators: Distribution by Location of Headquarters (Region)

Table 13.4 Plasma Fractionators: Distribution by Location of Headquarters (Country)

Table 13.5 Plasma Fractionators: Distribution by Year of Establishment and Location of Headquarters (Region)

Table 13.6 Plasma Fractionators: Distribution by Company Size and Location of Headquarters (Region)

Table 13.7 Plasma Fractionators: Distribution by Type of Company

Table 13.8 Plasma Fractionators: Distribution by Location of Plasma Fractionation Facilities (Region)

Table 13.9 Plasma Fractionators: Distribution by Location of Plasma Collection Facility

Table 13.10 Plasma Fractionators: Distribution by Availability of Patented / Proprietary Technology

Table 13.11 Plasma Fractionators: Distribution by Additional Fractionation Capabilities

Table 13.12 Plasma Fractionators: Distribution by Scale of Operation

Table 13.13 Plasma Fractionators: Distribution by Type of Plasma-derived Therapeutic Products Manufactured

Table 13.14 Plasma Fractionators: Distribution by Therapeutic Areas of Plasma-derived Products

Table 13.15 Plasma Fractionators: Distribution by End Users

Table 13.16 Baxter: Annual Revenues, 2018-Q1 2023 (USD Billion)

Table 13.17 Grifols: Annual Revenues, 2018-Q1 2023 (EUR Million)

Table 13.18 Kedrion: Annual Revenues, 2018-2022 (EUR Million)

Table 13.19 Octapharma: Annual Revenues, 2018-2022 (EUR Billion)

Table 13.20 CSL: Annual Revenues, FY 2018 - H1 FY 2023 (USD Million)

Table 13.21 Takeda Pharmaceutical: Annual Revenues, FY 2018 - FY 2022 (JPY Billion)

Table 13.22 Partnerships and Collaborations: Cumulative Year-wise Distribution of Partnerships

Table 13.23 Partnerships and Collaborations: Distribution by Type of Partnership

Table 13.24 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Table 13.25 Partnerships and Collaborations: Distribution by Purpose of Agreement

Table 13.26 Partnerships and Collaborations: Distribution by Type of Plasma-derived Therapeutic Products Manufactured

Table 13.27 Partnerships and Collaborations: Distribution by Type of Partner

Table 13.28 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner

Table 13.29 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner

Table 13.30 Most Active Players: Distribution by Number of Partnerships

Table 13.31 Partnerships and Collaborations: Distribution by Local and International Agreements

Table 13.32 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements

Table 13.33 Recent Expansions: Cumulative Year-wise Distribution of Expansions

Table 13.34 Recent Expansions: Distribution by Type of Expansion

Table 13.35 Recent Expansions: Distribution by Year and Type of Expansion

Table 13.36 Recent Expansions: Distribution by Type of Facility

Table 13.37 Recent Expansions: Distribution by Location of Expanded Facility

Table 13.38 Recent Expansions: Distribution by Year and Location of Expanded Facility

Table 13.39 Recent Expansions: Distribution by Plasma-derived Therapeutic Products Manufactured

Table 13.40 Most Active Players: Distribution by Number of Expansions

Table 13.41 Annual Plasma Fractionation Capacity: Distribution by Range of Installed Capacity

Table 13.42 Annual Plasma Fractionation Capacity: Distribution by Company Size

Table 13.43 Annual Plasma Fractionation Capacity: Distribution by Type of Plasma-derived Therapeutic Products Manufactured

Table 13.44 Annual Plasma Fractionation Capacity: Distribution by Scale of Operation

Table 13.45 Plasma Fractionation Capacity: Distribution by Location of Plasma Fractionation Facilities

Table 13.46 Plasma Fractionation Capacity: Distribution by Location of Headquarters (in Million Liters)

Table 13.47 Global Plasma Fractionation Market (Historical, Base and Forecasted Scenario), 2017-2035 (USD Billion)

Table 13.48 Plasma Fractionation Market: Distribution by Type of Company, 2017, 2023 and 2035 (USD Billion)

Table 13.49 Plasma Fractionation Market for In-house Manufacturers, 2023-2035 (USD Billion)

Table 13.50 Plasma Fractionation Market for Contract Service Providers, 2023-2035 (USD Billion)

Table 13.51 Plasma Fractionation Market: Distribution by Scale of Operation, 2017, 2023 and 2035 (USD Billion)

Table 13.52 Plasma Fractionation Market for Preclinical Operations, 2023-2035 (USD Billion)

Table 13.53 Plasma Fractionation Market for Clinical Operations, 2023-2035 (USD Billion)

Table 13.54 Plasma Fractionation Market for Commercial Operations, 2023-2035 (USD Billion)

Table 13.55 Plasma Fractionation Market: Distribution by Type of Plasma-derived Therapeutic Products Manufactured, 2017, 2023 and 2035 (USD Billion)

Table 13.56 Plasma Fractionation Market for Albumins, 2023-2035 (USD Billion)

Table 13.57 Plasma Fractionation Market for Coagulation Factors, 2023-2035 (USD Billion)

Table 13.58 Plasma Fractionation Market for Immunoglobulins, 2023-2035 (USD Billion)

Table 13.59 Plasma Fractionation Market for Protease Inhibitors, 2023-2035 (USD Billion)

Table 13.60 Plasma Fractionation Market for Other Plasma-derived Products, 2023-2035 (USD Billion)

Table 13.61 Plasma Fractionation Market: Distribution by Therapeutic Areas of Plasma-derived Products, 2017, 2023 and 2035 (USD Billion)

Table 13.62 Plasma Fractionation Market for Hematological Disorders, 2023-2035 (USD Billion)

Table 13.63 Plasma Fractionation Market for Hepatic Disorders, 2023-2035 (USD Billion)

Table 13.64 Plasma Fractionation Market for Immunological Disorders, 2023-2035 (USD Billion)

Table 13.65 Plasma Fractionation Market for Neurological Disorders, 2023-2035 (USD Billion)

Table 13.66 Plasma Fractionation Market for Other Disorders, 2023-2035 (USD Billion)

Table 13.67 Plasma Fractionation Market: Distribution by Demand across Key Geographical Regions, 2017, 2023 and 2035 (USD Billion)

Table 13.68 Plasma Fractionation Market for North America, 2023-2035 (USD Billion)

Table 13.69 Plasma Fractionation Market for Europe, 2023-2035 (USD Billion)

Table 13.70 Plasma Fractionation Market for Asia-Pacific, 2023-2035 (USD Billion)

Table 13.71 Plasma Fractionation Market for Rest of the World, 2023-2035 (USD Billion)

Table 13.72 Plasma Fractionation Market: Distribution by Supply across Key Geographical Regions, 2017, 2023 and 2035 (USD Billion)

Table 13.73 Plasma Fractionation Market for North America, 2023-2035 (USD Billion)

Table 13.74 Plasma Fractionation Market for Europe, 2023-2035 (USD Billion)

Table 13.75 Plasma Fractionation Market for Asia-Pacific, 2023-2035 (USD Billion)

Table 13.76 Plasma Fractionation Market for Rest of the World, 2023-2035 (USD Billion)